https://www.selleckchem.com/pr....oducts/vazegepant-hy
To review the clinical characteristics, antibodies, and response to alternative treatments in a cohort of patients with refractory CIDP. We reviewed the charts of all CIDP patients seen at the Oregon Health Science University neuromuscular clinic between 2017 and 2019. We collected demographics, clinical characteristics, antibodies, and response to treatments. Among 45 CIDP patients studied, 34 (76%) showed improvement with first-line therapy (steroids, IVIG and/or plasmapheresis) and 11 (24%) were considered refr
Like
Comment
Share
